Recurrent glioblastoma
3D Conformal Re Irradiation with Temozolamide for Recurrent Glioblastoma: A Prospective Cohort Study
... of recurrent Glioblastoma (GBM) is one of the most challenging tasks in ...for recurrent GBM as options include resection, chemo- therapy, and re-irradiation either separate or in ...in ...
13
Long-Term Survival after Gamma Knife Radiosurgery in a Case of Recurrent Glioblastoma Multiforme: A Case Report and Review of the Literature
... with recurrent glioblastoma who survived seven years following treatment with GK ...the recurrent setting can significantly impact overall survival for specific ...
7
<p>Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies</p>
... with recurrent glioblastoma and transfu- sion-dependent patients with low- and intermediate-risk ...with recurrent glioblastoma rando- mized to asunercept 400 mg/week plus radiotherapy or ...
6
Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics
... 22 recurrent glioblastoma taken from the Chinese population, and further analyzed biological progression of the tumors, when compared with primary ...in recurrent ones (22%) was lower than that in ...
7
Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials
... Based on the baseline data from these RCTs, we found two key factors that probably influenced the results. One was whether bevacizumab was used as the single-agent therapy, the other one was whether more than 50% ...
13
Serial MR in gene therapy for recurrent glioblastoma: initial experience and work in progress
... not complete more than one gene therapy cycle and were excluded from the data analysis. Pa- tient characteristics and outcomes are summa- rized in the Table. At surgery, all patients had evidence of recurrent ...
6
Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study
... Abstract: Local recurrence represents a significant challenge in the management of patients with glioblastoma multiforme. Salvage treatment options are limited by lack of clinical efficacy. Recent studies have ...
6
<p>Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study</p>
... Objective: This study aimed to determine the ef fi cacy and tolerability of apatinib plus dose- dense temozolomide (TMZ) as fi rst-line treatment for recurrent glioblastoma (rGBM). Methods: Patients with rGBM ...
7
Pretreatment ADC Histogram Analysis Is a Predictive Imaging Biomarker for Bevacizumab Treatment but Not Chemotherapy in Recurrent Glioblastoma
... MATERIALS AND METHODS: Eighty-nine bevacizumab-treated and 43 chemotherapy-treated recurrent glioblastoma multiformes never exposed to bevacizumab were included in this study. In all patients, ADC values in ...
7
Case of Advanced Recurrent Glioblastoma Successfully Treated with Monoterpene Perillyl Alcohol by Intranasal Administration
... of recurrent glioblastoma (GBM) successfully treated with the Ras inhibitor monoterpene perillyl al- cohol by intranasal ...of recurrent glioma without clinical and laboratory ...
6
Prognostic Factors in Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma Treated with Selective Intra arterial Chemotherapy
... RESULTS: Of 46 patients included in this study, 41 underwent evaluation. Thirty were male and 11 were female; mean age was 48.5 years. Karnofsky scores ranged from 70 to 100. Thirty- two patients had glioblastoma ...
8
Extended Daily Schedule of Temozolomide in Recurrent Glioblastoma: Single Institution Report on a Series of 43 Patients
... GBM patients [2-4]. By contrast, for patients with recur- rent or progressive disease, there is still no consensus as to the optimal second-line treatment of GBM recurrent patients, and many options are generally ...
12
The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma
... In this pilot feasibility study, we utilized MDC to deter- mine the neuropharmacokinetics of temozolomide co- administered with regadenoson to assess temozolomide drug entry. We hypothesized that regadenoson would ...
9
38-month long progression-free and symptom-free survival of a patient with recurrent glioblastoma multiforme: A case report of the Paleolithic Ketogenic Diet (PKD) used as a stand-alone treatment after failed standard oncotherapy
... Currently, there are only case studies that report on long-term survival benefit in cancer due to the ketogenic diet. One case study about two children with astrocytoma dates back to 1995 (Nebeling et al., 1995). Another ...
13
Hypofractionated Re irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival
... We note that our current study was limited by a small cohort and the risk of selection bias. Furthermore, our study featured some flaws in patient composition. Our cohort comprised of patients with both secondary and ...
8
Recurrent Glioblastoma Multiforme—A Strategy for Long Term Survival
... Recurrent GBM (RGBM) has a highly unfavorable prognosis with majority of patients dying within 6 months and no standard treatments available. Antineoplaston (ANP) A10 and AS2-1 injections underwent Phase II trials ...
21
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
... In summary, we have established the pipeline for a trans- lational clinical protocol targeting glioblastoma stem cells in recGBM utilizing automated drug sensitivity testing. We found an extensive intertumoral ...
15
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy
... Background: Glioblastoma multiforme (GBM) is a relentless primary central nervous system malignancy that remains resistant to conventional therapy despite major advances in clinical ...for recurrent GBM and ...
6
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
... Currently, the PI3K inhibitors as a single agent or combined with other therapies are being tested in a number of clinical trials (Table 2) [43]. There are pan- PI3K inhibitors and isoform specific PI3K inhibitors [14]. ...
11
Passing across the blood-brain barrier in glioblastoma multiforme (GBM)
... therapeutic potential in chemotherapy is ultrasound-mediated drug delivery (USMD). In USMD, microbubbles with a diameter of 1-10 microns are used to mechanically break cell junctions and ultrasound waves, which are aimed ...
8